Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CRISPR Therapeutics Q2 2024 Adj EPS $(1.49) Beats $(1.52) Estimate, Sales $517.00K May Not Compare To $3.54M Estimate

Author: Benzinga Newsdesk | August 05, 2024 04:07pm
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.49) per share which beat the analyst consensus estimate of $(1.52) by 1.97 percent. The company reported quarterly sales of $517.00 thousand which missed the analyst consensus estimate of $3.54 million by 85.39 percent. This is a 99.26 percent decrease over sales of $70.00 million the same period last year.

Posted In: CRSP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist